» Articles » PMID: 17475791

Catechol O-methyltransferase Val158Met Genotype Influences Frontoparietal Activity During Planning in Patients with Parkinson's Disease

Overview
Journal J Neurosci
Specialty Neurology
Date 2007 May 4
PMID 17475791
Citations 80
Authors
Affiliations
Soon will be listed here.
Abstract

Cognitive dysfunction commonly occurs even in the early stages of Parkinson's disease (PD). Impairment on frontostriatally based executive tasks is particularly well described but affects only a proportion of early PD patients. Our previous work suggests that a common functional polymorphism (val(158)met) within the catechol O-methyltransferase (COMT) gene underlies some of this executive heterogeneity. In particular, an increasing number of methionine alleles, resulting in lower enzyme activity, is associated with impaired performance on the "Tower of London" planning task. The main objective of this study was to investigate the underlying neural basis of this genotype-phenotype effect in PD using functional magnetic resonance imaging. We scanned 31 patients with early PD who were homozygous for either valine (val) (n = 16) or methionine (met) (n = 15) at the COMT val(158)met polymorphism during performance of an executive task comprising both Tower of London (planning) and simple subtracting ("control") problems. A cross-group comparison between genetic subgroups revealed that response times for planning problems were significantly longer in met compared with val homozygotes, whereas response times for control problems did not differ. Furthermore, imaging data revealed a significant reduction in blood oxygen level-dependent signal across the frontoparietal network involved in planning in met/met compared with val/val patients. Hence, we have demonstrated that COMT genotype impacts on executive function in PD through directly influencing frontoparietal activation. Furthermore, the directionality of the genotype-phenotype effect observed in this study, when interpreted in the context of the existing literature, adds weight to the hypothesis that the relationship between prefrontal function and dopamine levels follows as an inverted U-shaped curve.

Citing Articles

A design for life: Predicting cognitive performance from lifestyle choices.

Nichols E, Nelson G, Wild C, Owen A PLoS One. 2024; 19(4):e0298899.

PMID: 38626013 PMC: 11020841. DOI: 10.1371/journal.pone.0298899.


Dopamine in the prefrontal cortex plays multiple roles in the executive function of patients with Parkinson's disease.

Zhou Z, Yan Y, Gu H, Sun R, Liao Z, Xue K Neural Regen Res. 2023; 19(8):1759-1767.

PMID: 38103242 PMC: 10960281. DOI: 10.4103/1673-5374.389631.


Huntington disease exacerbates action impulses.

Shiino S, van Wouwe N, Wylie S, Claassen D, McDonell K Front Psychol. 2023; 14:1186465.

PMID: 37397312 PMC: 10312388. DOI: 10.3389/fpsyg.2023.1186465.


Pre-operative cognitive burden as predictor of motor outcome following bilateral subthalamic nucleus deep brain stimulation in Parkinson's disease.

Tang V, Zhu X, Lau C, Chan A, Ma K, Yeung J Neurol Sci. 2022; 43(12):6803-6811.

PMID: 36048377 DOI: 10.1007/s10072-022-06370-8.


Progressive Prefrontal Cortex Dysfunction in Parkinson's Disease With Probable REM Sleep Behavior Disorder: A 3-Year Longitudinal Study.

Jia X, Fan W, Wang Z, Liu Y, Li Y, Li H Front Aging Neurosci. 2022; 13:750767.

PMID: 35082656 PMC: 8784770. DOI: 10.3389/fnagi.2021.750767.


References
1.
Manoach D, Press D, Thangaraj V, Searl M, Goff D, Halpern E . Schizophrenic subjects activate dorsolateral prefrontal cortex during a working memory task, as measured by fMRI. Biol Psychiatry. 1999; 45(9):1128-37. DOI: 10.1016/s0006-3223(98)00318-7. View

2.
Rakshi J, Uema T, Ito K, Bailey D, Morrish P, Ashburner J . Frontal, midbrain and striatal dopaminergic function in early and advanced Parkinson's disease A 3D [(18)F]dopa-PET study. Brain. 1999; 122 ( Pt 9):1637-50. DOI: 10.1093/brain/122.9.1637. View

3.
Dagher A, Owen A, Boecker H, Brooks D . Mapping the network for planning: a correlational PET activation study with the Tower of London task. Brain. 1999; 122 ( Pt 10):1973-87. DOI: 10.1093/brain/122.10.1973. View

4.
Goldman-Rakic P, Muly 3rd E, Williams G . D(1) receptors in prefrontal cells and circuits. Brain Res Brain Res Rev. 2000; 31(2-3):295-301. DOI: 10.1016/s0165-0173(99)00045-4. View

5.
Schrag A, Jahanshahi M, Quinn N . What contributes to quality of life in patients with Parkinson's disease?. J Neurol Neurosurg Psychiatry. 2000; 69(3):308-12. PMC: 1737100. DOI: 10.1136/jnnp.69.3.308. View